IL259023A - Compositions containing protein loaded exosomes and methods for preparing same and uses thereof - Google Patents

Compositions containing protein loaded exosomes and methods for preparing same and uses thereof

Info

Publication number
IL259023A
IL259023A IL259023A IL25902318A IL259023A IL 259023 A IL259023 A IL 259023A IL 259023 A IL259023 A IL 259023A IL 25902318 A IL25902318 A IL 25902318A IL 259023 A IL259023 A IL 259023A
Authority
IL
Israel
Prior art keywords
methods
compositions containing
containing protein
preparing same
protein loaded
Prior art date
Application number
IL259023A
Other languages
Hebrew (he)
Other versions
IL259023B (en
Original Assignee
Cellex Life Sciences Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160126335A external-priority patent/KR101877010B1/en
Priority claimed from KR1020160126961A external-priority patent/KR101912315B1/en
Priority claimed from KR1020160126921A external-priority patent/KR101912313B1/en
Priority claimed from KR1020160127486A external-priority patent/KR101912310B1/en
Priority claimed from KR1020160132616A external-priority patent/KR101900465B1/en
Application filed by Cellex Life Sciences Incorporated filed Critical Cellex Life Sciences Incorporated
Publication of IL259023A publication Critical patent/IL259023A/en
Publication of IL259023B publication Critical patent/IL259023B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01015—Peroxiredoxin (1.11.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
IL259023A 2016-09-30 2017-09-29 Compositions containing protein loaded exosomes and methods for preparing same and uses thereof IL259023B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR1020160126335A KR101877010B1 (en) 2016-09-30 2016-09-30 Process for preparing exosome loading super-repressor-IκB protein, and pharmaceutical composition for use in preventing or treating inflammatory diseases containing the same as an active ingredient
KR1020160126961A KR101912315B1 (en) 2016-09-30 2016-09-30 Process for preparing exosome loading Bcl-2-associated X protein, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
KR1020160126921A KR101912313B1 (en) 2016-09-30 2016-09-30 Process for preparing exosome loading cre recombinase, and pharmaceutical composition for use in generating conditional knock-out alleles containing the same as an active ingredient
KR1020160127486A KR101912310B1 (en) 2016-10-04 2016-10-04 Process for preparing exosome loading Peroxiredoxin I or II protein, and pharmaceutical composition for use in antioxidant containing the same as an active ingredient
KR1020160132616A KR101900465B1 (en) 2016-10-13 2016-10-13 Technology to deliver the genome editing tool by using the CRISPR-CAS family
KR20170018637 2017-02-10
PCT/KR2017/011070 WO2018062973A1 (en) 2016-09-30 2017-09-29 Compositions containing protein loaded exosome and methods for preparing and delivering the same

Publications (2)

Publication Number Publication Date
IL259023A true IL259023A (en) 2018-07-31
IL259023B IL259023B (en) 2022-09-01

Family

ID=61760013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259023A IL259023B (en) 2016-09-30 2017-09-29 Compositions containing protein loaded exosomes and methods for preparing same and uses thereof

Country Status (7)

Country Link
EP (1) EP3356522A4 (en)
JP (1) JP2019528674A (en)
CN (1) CN108473973A (en)
AU (1) AU2017335084B2 (en)
CA (1) CA3002520A1 (en)
IL (1) IL259023B (en)
WO (1) WO2018062973A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307890A1 (en) * 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
US10709797B2 (en) 2017-08-16 2020-07-14 City University Of Hong Kong Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
CA3095716A1 (en) * 2018-04-10 2019-10-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
CN110387416B (en) * 2018-04-16 2022-06-17 华东理工大学 Nano-gold dual-probe system with controllable polymerization regulation function and application thereof
WO2020023594A1 (en) * 2018-07-24 2020-01-30 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
CN110885789A (en) * 2018-09-05 2020-03-17 中国科学院生物物理研究所 Preparation of engineered exosome of efficient controllable packaging endogenous nucleic acid and application thereof
CN109097336A (en) * 2018-09-07 2018-12-28 深圳市新仑生物科技有限公司 A kind of stem cell excretion body, preparation method and application
JP2022513311A (en) * 2018-09-21 2022-02-07 シティー・ユニバーシティー・オブ・ホンコン Cargo-loaded extracellular vesicles
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
KR102125567B1 (en) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 Large-Scale Production of Plant Derived Exosomes
CN110669723A (en) * 2019-11-08 2020-01-10 赵凯 Differential centrifugation method-based cell exosome extraction process
WO2021138446A1 (en) * 2019-12-30 2021-07-08 Ilias Biologics Inc. COMPOSITIONS CONTAINING EXOSOME CARRYING NF-kB INHIBITORS AND METHODS OF USING THEREOF
KR20220127851A (en) 2020-01-13 2022-09-20 카민 테라퓨틱스 피티이. 엘티디. Nucleic acid-loaded red blood cells extracellular vesicles
EP4104860A4 (en) 2020-02-10 2024-03-06 Exostemtech Co., Ltd. Exosome comprising photocleavable protein, and use thereof
KR102688170B1 (en) 2020-02-10 2024-07-24 주식회사 엑소스템텍 Exosome comprising photocleavable protein and Use thereof
CN113388584A (en) * 2020-03-10 2021-09-14 路宝特（南京）环保科技有限公司 Preparation method and application of engineered exosome for promoting skin tissue damage repair
CA3173845A1 (en) * 2020-03-31 2021-10-07 Chulhee Choi Use of exosome-based delivery of nf-kb inhibitors
CN111905105B (en) * 2020-07-02 2023-05-05 华南师范大学 Protein nano-drug for cancer targeted therapy and preparation method thereof
CN114716548A (en) 2021-01-05 2022-07-08 (株)爱恩德生物 anti-FGFR 3 antibodies and uses thereof
CN113234686A (en) * 2021-04-28 2021-08-10 大连干细胞与精准医学创新研究院 Preparation method of target protein delivery carrier
CN114878833A (en) * 2021-07-01 2022-08-09 浙江大学 Kit for detecting anti-peroxiredoxin-1-IgG antibody
CN116355858A (en) * 2023-05-29 2023-06-30 北京大学 Engineered extracellular vesicles for delivering CRISPR-Cas9, and preparation method and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
US7704964B2 (en) * 2001-08-17 2010-04-27 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
KR100519384B1 (en) 2002-08-13 2005-10-06 (주)누백스 Manufacturing method of exosomes using gene transfection and use of the same
US8216784B2 (en) 2007-07-25 2012-07-10 University Of Louisville Research Foundation, Inc. Cancer-derived microvesicle-associated microrna as a diagnostic marker
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
AU2010268367B2 (en) * 2009-07-02 2016-10-20 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
FR2950350B1 (en) * 2009-09-24 2013-12-13 Centre Nat Rech Scient NOVEL POLYNUCLEOTIDES AND CHIMERIC POLYPEPTIDES FOR THE SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND USES THEREOF
SG183579A1 (en) * 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2013048185A2 (en) * 2011-09-30 2013-04-04 한국과학기술원 Method for forming a reversible protein nanocluster using light in a cell
WO2013089738A1 (en) * 2011-12-15 2013-06-20 Morehouse School Of Medicine Compositions and methods for exosome targeted expression
KR101433057B1 (en) * 2012-03-07 2014-09-23 한국과학기술원 Fusion proteins capable of activating receptor tyrosine kinase signalling pathway by light and uses thereof
JP6542197B2 (en) * 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド Therapeutic delivery vesicles
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN103468642A (en) * 2013-09-23 2013-12-25 山西大学 Method for separating exosome from cell culture medium
ES2929725T3 (en) * 2014-05-18 2022-12-01 Childrens Medical Center Methods and compositions related to exosomes
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
JP2017535599A (en) * 2014-11-07 2017-11-30 ウィスコンシン アラムニ リサーチ ファンデーション B cell target DNA vaccine
WO2016143805A1 (en) * 2015-03-10 2016-09-15 テオリアサイエンス株式会社 Method for detecting bladder cancer
KR20160130937A (en) * 2015-05-04 2016-11-15 한국과학기술원 Process for preparing exosome loading target protein and method for loading target protein to cytosol by using exosome prepared thereby

Also Published As

Publication number Publication date
CN108473973A (en) 2018-08-31
WO2018062973A1 (en) 2018-04-05
JP2019528674A (en) 2019-10-17
CA3002520A1 (en) 2018-04-05
EP3356522A4 (en) 2019-03-27
IL259023B (en) 2022-09-01
EP3356522A1 (en) 2018-08-08
AU2017335084B2 (en) 2023-06-29
AU2017335084A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
IL259023A (en) Compositions containing protein loaded exosomes and methods for preparing same and uses thereof
IL267034A (en) Methods and compositions for nucleic acid and protein payload delivery
IL262321A (en) Compositions and methods for selective protein expression
HK1247854A1 (en) Mixed allergen compositions and methods for using the same
HK1253306A1 (en) Anti-ntb-a antibodies and related compositions and methods
HK1255210A1 (en) Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
HK1224376A1 (en) Methods and compositions for isolating exosomes
IL265796A (en) Compositions comprising pedf-derived short peptides and uses thereof
HK1249174A1 (en) Compositions and methods for capturing exosomes
HK1254822A1 (en) Compositions and methods for decreasing tau expression
HK1248561A1 (en) Water-in-oil cosmetic composition comprising porous polyhedral powder
IL265831A (en) Compositions and methods for protein expression and delivery
IL265965A (en) Methods and compositions for tusc2 immunotherapy
IL268997A (en) Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
EP3319930A4 (en) Methods and compositions for the stabilizaton of proteins
PL3072529T3 (en) Composition comprising vemurafenib and hpmc-as
EP3324971C0 (en) Zolpidem composition and process for preparing the same
ZA201503861B (en) Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof